The DOI matches its Crossref record; 272 of the 272 references it cites were found in a registry or an index.
Bridging Bio–Nano Science and Cancer Nanomedicine
Abstract
The interface of bio-nano science and cancer medicine is an area experiencing much progress but also beset with controversy. Core concepts of the field-e.g., the enhanced permeability and retention (EPR) effect, tumor targeting and accumulation, and even the purpose of "nano" in cancer medicine-are hotly debated. In parallel, considerable advances in neighboring fields are occurring rapidly, including the recent progress of "immuno-oncology" and the fundamental impact it is having on our understanding and the clinical treatment of the group of diseases collectively known as cancer. Herein, we (i) revisit how cancer is commonly treated in the clinic and how this relates to nanomedicine; (ii) examine the ongoing debate on the relevance of the EPR effect and tumor targeting; (iii) highlight ways to improve the next-generation of nanomedicines; and (iv) discuss the emerging concept of working with (and not against) biology. While discussing these controversies, challenges, emerging concepts, and opportunities, we explore new directions for the field of cancer nanomedicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–272 of 272
Nanoparticles for radiooncology: Mission, vision, challenges
Kunz‐Schughart, L. A., Dubrovska, A., Peitzsch, C., Ewe, A., Aigner, A. M., Schellenburg, S., Muders, M. H., Hampel, S., Cirillo, G., Iemma, F., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.12.010 · Cited by 110
New Strategies in Cancer Nanomedicine
Tong, R., & Kohane, D. S. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103456 · Cited by 109
Reuter, K. G., Perry, J. L., Kim, D., Luft, J. C., Liu, R., & DeSimone, J. M. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b01362 · Cited by 101
Mapping of Molecular Structure of the Nanoscale Surface in Bionanoparticles
Herda, L. M., Hristov, D. R., Lo Giudice, M. C., Polo, E., & Dawson, K. A. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b12297 · Cited by 100
Nanoparticulate immunotherapy for cancer
Kapadia, C. H., Perry, J. L., Tian, S., Luft, J. C., & DeSimone, J. M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.062 · Cited by 98
Ekdawi, S. N., Stewart, J., Dunne, M., Stapleton, S., Mitsakakis, N., Dou, Y. N., Jaffray, D. A., & Allen, C. J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.006 · Cited by 94
Harrington, K. J., Rowlinson‐Busza, G., Syrigos, K. N., Abra, R. M., Uster, P. S., Peters, A. M., & Stewart, J. S. W. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1320 · Cited by 91
Successful imaging of human cancer with indium-111-labeled phospholipid vesicles
Presant, C. A., Proffitt, R. T., Turner, A., Williams, L. E., Winsor, D. T., Werner, J. L., Kennedy, P., Wiseman, C. L., Gala, K. V., McKenna, R. J., et al. (1988) · Cancer · Cited by 89
Particle Carriers for Combating Multidrug-Resistant Cancer
Yan, Y., Björnmalm, M., & Caruso, F. (2013) · ACS Nano · doi:10.1021/nn405632s · Cited by 89
Self-citationIn vitromicrofluidic models of tumor microenvironment to screen transport of drugs and nanoparticles
Özçelikkale, A., Moon, H., Linnes, M. P., & Han, B. (2017) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1460 · Cited by 89
Transforming Nanomedicines From Lab Scale Production to Novel Clinical Modality
Landesman‐Milo, D., & Peer, D. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00607 · Cited by 88
18F-Labeled-Bioorthogonal Liposomes for In Vivo Targeting
Emmetiere, F., Irwin, C., Viola, N. T., Longo, V. A., Cheal, S. M., ZANZONICO, P. B., Pillarsetty, N., Weber, W., Lewis, J. S., & Reiner, T. (2013) · Bioconjugate Chemistry · doi:10.1021/bc400322h · Cited by 87
Solomon, B., Desai, J., Rosenthal, M. A., McArthur, G. A., Pattison, S. T., Pattison, S. L., MacDiarmid, J. A., Brahmbhatt, H. N., & Scott, A. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144559 · Cited by 87
Self-citationAntibody-Targeted Biodegradable Nanoparticles for Cancer Therapy
Shargh, V. H., Hondermarck, H., & Liang, M. (2015) · Nanomedicine · doi:10.2217/nnm.15.186 · Cited by 87
Drug delivery of the future: Chasing the invisible gorilla
Park, K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.048 · Cited by 86
Nanoengineering Particles through Template Assembly
Björnmalm, M., Cui, J., Bertleff‐Zieschang, N., Song, D., Faria, M., Rahim, M. A., & Caruso, F. (2016) · Chemistry of Materials · doi:10.1021/acs.chemmater.6b02848 · Cited by 86
Self-citationJohnston, A. P. R., Kamphuis, M. M. J., Such, G. K., et al. (2012) · ACS Nano · doi:10.1021/nn3010476 · Cited by 85
Nanomedicine and tumor heterogeneity: Concept and complex reality
Ekdawi, S. N., Jaffray, D. A., & Allen, C. J. (2016) · Nano Today · doi:10.1016/j.nantod.2016.06.006 · Cited by 83
Haddish‐Berhane, N., Shah, D. K., Ma, D., Leal, M., Gerber, H., Sapra, P., Barton, H. A., & Betts, A. M. (2013) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-013-9329-x · Cited by 79
Presant, C. A., Blayney, D. W., Kennedy, P., Wiseman, C. L., Gala, K. V., Presant, S., Proffitt, R. T., Crossley, R. J., Preiss, S. J., Ksionski, G., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)91188-g · Cited by 79
Tanei, T., Leonard, F., Liu, X., Alexander, J. F., Saito, Y., Mauro Ferrari, B., Godin, B., & Yokoi, K. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1576 · Cited by 78
From Composition to Cure: A Systems Engineering Approach to Anticancer Drug Carriers
MacEwan, S. R., & Chilkoti, A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201610819 · Cited by 78
Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies
Liu, J., Blake, S. J., Smyth, M. J., & Teng, M. W. L. (2014) · Clinical & Translational Immunology · doi:10.1038/cti.2014.18 · Cited by 77
Targeting distinct myeloid cell populations in vivo using polymers, liposomes and microbubbles
Ergen, C., Heymann, F., Rawashdeh, W. A., Gremse, F., Bartneck, M., Panzer, U., Pola, R., Pechar, M., Storm, G., Mohr, N., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.11.009 · Cited by 77
Just so stories: The random acts of anti-cancer nanomedicine performance
Moghimi, S. M., & Farhangrazi, Z. S. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.04.011 · Cited by 75
Defining the Value of a Comparative Approach to Cancer Drug Development
LeBlanc, A. K., Mazcko, C. N., & Khanna, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2347 · Cited by 75
Singh, R., Nörret, M., House, M. J., Galabura, Y., Bradshaw, M., Ho, D., Woodward, R. C., Pierre, T. G. S., Luzinov, I. A., Smith, N. M., et al. (2015) · Small · doi:10.1002/smll.201502730 · Cited by 71
A Rapid Method for studying Tumour Blood Supply using Systemic Dyes
Goldacre, R. J., & Sylvén, B. (1959) · Nature · doi:10.1038/184063a0 · Cited by 70
Howard, C. B., Fletcher, N. L., Houston, Z. H., Fuchs, A. V., Boase, N. R. B., Simpson, J. D., Raftery, L. J., Ruder, T., Jones, M. L., de Bakker, C. J., et al. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201600263 · Cited by 70
Self-citationYu, M., Zhou, C., Liu, L., Zhang, S., Sun, S., Hankins, J. D., Sun, X., & Zheng, J. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201612647 · Cited by 70
Human Tumor Xenografts: The Good, the Bad, and the Ugly
Morgan, R. A. (2012) · Molecular Therapy · doi:10.1038/mt.2012.73 · Cited by 69
Cancer Targeted Drug Delivery: An Elusive Dream
(2013) · doi:10.1007/978-1-4614-7876-8 · Cited by 67
Langer, R., & Weissleder, R. (2015) · JAMA · doi:10.1001/jama.2014.16315 · Cited by 65
Increasing the Impact of Materials in and beyond Bio-Nano Science
Björnmalm, M., Faria, M., & Caruso, F. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b08673 · Cited by 63
Self-citationManshian, B., Jiménez, J., Himmelreich, U., & Soenen, S. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.02.039 · Cited by 63
Nilvebrant, J., Åstrand, M., Georgieva-Kotseva, M., Björnmalm, M., Löfblom, J., & Hober, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103094 · Cited by 62
Self-citationWang, Y., & Huang, L. (2013) · Nature Biotechnology · doi:10.1038/nbt.2634 · Cited by 62
Dai, Q., Yan, Y., Guo, J., Björnmalm, M., Cui, J., Sun, H., & Caruso, F. (2015) · ACS Macro Letters · doi:10.1021/acsmacrolett.5b00627 · Cited by 61
Self-citationImmunotherapy Via Dendritic Cells
Palucka, A. K., Laupèze, B., Aspord, C., Saito, H., Jégo, G., Fay, J. W., Paczesny, S., Pascual, V., & Banchereau, J. (2005) · Advances in experimental medicine and biology · doi:10.1007/0-387-24180-9_14 · Cited by 60
Mulvaney, P. A., Parak, W. J., Caruso, F., & Weiss, P. S. (2016) · ACS Nano · doi:10.1021/acsnano.6b07629 · Cited by 60
Self-citationAre High Drug Loading Nanoparticles The Next Step Forward for Chemotherapy?
Rocca, J. D., Liu, D., & Lin, W. (2012) · Nanomedicine · doi:10.2217/nnm.11.191 · Cited by 59
Smith, B. R., Zavaleta, C. L., Rosenberg, J., Tong, R. T., Ramunas, J., Liu, Z., Dai, H., & Gambhir, S. S. (2013) · Nano Today · doi:10.1016/j.nantod.2013.02.004 · Cited by 57
Nanomedicine approaches to improve cancer immunotherapy
Qiu, H., Min, Y., Rodgers, Z., Zhang, L., & Wang, A. Z. (2017) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1456 · Cited by 54
Mimicking Tumors: Toward More Predictive In Vitro Models for Peptide- and Protein-Conjugated Drugs
van den Brand, D., Massuger, L. F. A. G., Brock, R. E., & Verdurmen, W. P. R. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00699 · Cited by 50
Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines
Balasubramanian, V., Liu, Z., Hirvonen, J. J., & Santos, H. A. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700432 · Cited by 49
Liposomal distribution in malignant glioma
KHALIFA, A., Dodds, D., Rampling, R., PATERSON, J., & Murray, T. J. (1997) · Nuclear Medicine Communications · doi:10.1097/00006231-199701000-00005 · Cited by 44
Advanced Strategies in Immune Modulation of Cancer Using Lipid-Based Nanoparticles
Mizrahy, S., Hazan‐Halevy, I., Landesman‐Milo, D., Ng, B. D., & Peer, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00069 · Cited by 44
Lessons from immuno-oncology: a new era for cancer nanomedicine?
Jiang, W., Yuan, H., Chan, C. K. F., Roemeling, C. A. V., Yan, Z., Weissman, I. L., & Kim, B. Y. S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.34 · Cited by 44
Evaluation of Polymeric Nanomedicines Targeted to PSMA: Effect of Ligand on Targeting Efficiency
Fuchs, A. V., Tse, B. W.-C., Pearce, A. K., Yeh, M.-C., Fletcher, N. L., Huang, S. S.-L., Heston, W. D. W., Whittaker, A. K., Russell, P. J., & Thurecht, K. J. (2015) · Biomacromolecules · doi:10.1021/acs.biomac.5b00913 · Cited by 43
Self-citationLu, Y., Wang, Y., Miao, L., Haynes, M. T., Xiang, G., & Huang, L. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.05.025 · Cited by 43
Reply to “Evaluation of nanomedicines: stick to the basics”
Wilhelm, S., Tavares, A. J., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.74 · Cited by 43
Role of Kupffer cells in the outgrowth of colorectal cancer liver metastases
Paschos, K. A., Majeed, A. W., & Bird, N. C. (2009) · Hepatology Research · doi:10.1111/j.1872-034x.2009.00578.x · Cited by 42
Cancer: Imaging with antibodies
Mestel, R. (2017) · Nature · doi:10.1038/543743a · Cited by 41
Antibodies as Carriers of Cytotoxicity
Sedlacek, H. H., Seemann, G., Hoffmann, D., et al. (1992) · Beiträge zur Onkologie/Contributions to oncology · doi:10.1159/isbn.978-3-318-03426-4 · Cited by 40
Tumor accumulation of liposomal doxorubicin in three murine models: Optimizing delivery efficiency
Dawidczyk, C. M., Russell, L. M., Hultz, M., & Searson, P. C. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.02.008 · Cited by 39
Lessons in simplicity that should shape the future of drug delivery
Raemdonck, K., & Smedt, S. C. D. (2015) · Nature Biotechnology · doi:10.1038/nbt.3366 · Cited by 36
Recommendations for Benchmarking Preclinical Studies of Nanomedicines
Dawidczyk, C. M., Russell, L. M., & Searson, P. C. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1558 · Cited by 34
Anselmo, A. C., Prabhakarpandian, B., Pant, K., & Mitragotri, S. (2017) · Translational Materials Research · doi:10.1088/2053-1613/aa5468 · Cited by 33
A precision approach to tumour treatment
Dienstmann, R., & Tabernero, J. M. (2017) · Nature · doi:10.1038/nature23101 · Cited by 32
Engineered Autonomous Human Variable Domains
Nilvebrant, J., Tessier, P. M., & Sidhu, S. S. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160921143011 · Cited by 30
Watching the gorilla and questioning delivery dogma
Anchordoquy, T. J., & Simberg, D. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.021 · Cited by 30
Molecular imaging in nanomedicine – A developmental tool and a clinical necessity
Dearling, J. L. J., & Packard, A. B. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.06.011 · Cited by 25
Announcement: Transparency upgrade for Nature journals
(2017) · Nature · doi:10.1038/543288b · Cited by 23
Simplicity as a Route to Impact in Materials Research
Tian, X., Lind, K. R., Yuan, B., et al. (2017) · Advanced Materials · doi:10.1002/adma.201604681 · Cited by 19
Song, G. K., Suzuki, O., Santos, C., Lucas, A. T., Wiltshire, T., & Zamboni, W. C. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.05.019 · Cited by 18
Can an Immune Checkpoint Inhibitor (Sometimes) Make Things Worse?
Sharon, E. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2926 · Cited by 18
Spence, T., Souza, R. D., Dou, Y. N., Stapleton, S., Reilly, R. M., & Allen, C. J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.036 · Cited by 15
Souza, R. D., Spence, T., Huang, H., & Allen, C. J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.041 · Cited by 14
Translation from mouse to human: Time to think in new boxes
Park, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.046 · Cited by 14
Braunger, J. A., Björnmalm, M., Isles, N. A., Cui, J., Henderson, T. M. A., O’Connor, A. J., & Caruso, F. (2016) · Biomaterials Science · doi:10.1039/c6bm00726k · Cited by 13
Self-citationImaging tumour distribution of a polymeric drug delivery platform in vivo by PET‐MRI
Puttick, S. G., Boase, N. R. B., Blakey, I., & Thurecht, K. J. (2014) · Journal of Chemical Technology & Biotechnology · doi:10.1002/jctb.4489 · Cited by 10
Self-citationTumour imaging with labelled liposomes
BRIELE, B., Hotze, A. L., Oehr, P., Biersack, H.-J., Rosanowski, F., Gorgulla, W., Herberhold, C., & Hartlapp, J. P. (1990) · The Lancet · doi:10.1016/0140-6736(90)92379-v · Cited by 7
Cited by
Targeting Tumor Microenvironment for Cancer Therapy
Roma-Rodrigues, C., Mendes, R., Baptista, P. V., & Fernandes, A. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040840 · Cited by 1,187
Fang, J., Islam, W., & Maeda, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.005 · Cited by 757
Minimum information reporting in bio–nano experimental literature
Faria, M., Björnmalm, M., Thurecht, K. J., Kent, S. J., Parton, R. G., Kavallaris, M., Johnston, A. P. R., Gooding, J. J., Corrie, S. R., Boyd, B. J., et al. (2018) · Nature Nanotechnology · doi:10.1038/s41565-018-0246-4 · Cited by 710
Self-citationOvercoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Self-citationZhou, Y., Chen, X., Cao, J., & Gao, H. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00649a · Cited by 213
Metadata
- Authors
- Björnmalm, M., Thurecht, K. J., Michael, M., Scott, A. M., & Caruso, F.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-09-19
- Volume
- 11
- Issue
- 10
- Pages
- 9594-9613
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2754708902
- Cited by
- 382
- References
- 272
- FWCI
- 14.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
